Age
Item
male or female subject 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Follicular Lymphoma Grade Any
Item
pathological diagnosis of follicular lymphoma (any grade)
boolean
C0024301 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
Recurrent disease Post Antineoplastic Therapy | Disease Progression Post Antineoplastic Therapy
Item
documented relapse or progression following prior antineoplastic therapy
boolean
C0277556 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C2346834 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C2346834 (UMLS CUI [2,3])
Rituximab Dose Quantity
Item
have received 4 or more prior doses of rituximab
boolean
C0393022 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Tumor Mass Measurable Quantity | Tumor Mass Long axis | Tumor Mass Short axis | Prior radiation therapy Absent | Tumor growth Post Prior radiation therapy
Item
at least 1 measurable tumor mass (>1.5 cm in the long axis and >1.0 cm in the short axis that has not been previously irradiated, or has grown since previous irradiation
boolean
C3273930 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3273930 (UMLS CUI [2,1])
C0522487 (UMLS CUI [2,2])
C3273930 (UMLS CUI [3,1])
C0522488 (UMLS CUI [3,2])
C0279134 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0598934 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
C0279134 (UMLS CUI [5,3])
Central nervous system lymphoma Absent
Item
no clinically significant central nervous system lymphoma
boolean
C0742472 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Karnofsky Performance Status | ECOG performance status
Item
karnofsky performance status (kps) ≥50 (equivalent to eastern cooperative group oncology group [ecog] status ≤2
boolean
C0206065 (UMLS CUI [1])
C1520224 (UMLS CUI [2])
Malignant Neoplasms | Cancer treatment | Exception Non-Hodgkin Lymphoma | Exception Therapeutic radiology procedure Prostate carcinoma | Exception Prostate specific antigen measurement | Exception Complete excision Basal cell carcinoma | Exception Complete excision Squamous cell carcinoma of skin | Exception Carcinoma in Situ Treated
Item
diagnosed or treated for a malignancy other than non-hodgkin's lymphoma (nhl) within 2 years of first dose, or who were previously diagnosed with a malignancy other than nhl and have any radiographic or biochemical marker evidence of malignancy. subjects with prostate cancer who were treated with definitive radiotherapy and have a serum prostate-specific antigen (psa) <1 ng/ml are not excluded. subjects are also not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated.
boolean
C0006826 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0024305 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1522449 (UMLS CUI [4,2])
C0600139 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0201544 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0015250 (UMLS CUI [6,2])
C0007117 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0015250 (UMLS CUI [7,2])
C0553723 (UMLS CUI [7,3])
C1705847 (UMLS CUI [8,1])
C0007099 (UMLS CUI [8,2])
C1522326 (UMLS CUI [8,3])
Velcade | Bendamustine
Item
prior treatment with velcade® or bendamustine
boolean
C1174739 (UMLS CUI [1])
C0525079 (UMLS CUI [2])
Antineoplastic Therapy | Monoclonal antibody unconjugated therapy | Toxin Immunoconjugates | Therapies, Investigational | Therapeutic radiology procedure
Item
antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before day 1 of cycle 1
boolean
C2346834 (UMLS CUI [1])
C0854644 (UMLS CUI [2])
C0040549 (UMLS CUI [3,1])
C0243020 (UMLS CUI [3,2])
C0949266 (UMLS CUI [4])
C1522449 (UMLS CUI [5])
Nitrosourea
Item
nitrosoureas within 6 weeks before day 1 of cycle 1
boolean
C0028210 (UMLS CUI [1])
Radioimmunoconjugates
Item
radioimmunoconjugates within 10 weeks before day 1 of cycle 1
boolean
C0243019 (UMLS CUI [1])
Transplantation of autologous hematopoietic stem cell | Allogeneic Stem Cell Transplantation
Item
autologous stem cell transplant within 3 months before day 1 of cycle 1, or prior allogeneic stem cell transplant at any time
boolean
C1831743 (UMLS CUI [1])
C2242529 (UMLS CUI [2])
Major surgery
Item
major surgery within 2 weeks before day 1 of cycle 1
boolean
C0679637 (UMLS CUI [1])
Platelet Transfusion
Item
platelet transfusion within 7 days of day 1 of cycle 1 (applies to subjects enrolled in the dose escalation phase only. this does not apply to subjects enrolled in phase 2 of the study).
boolean
C0086818 (UMLS CUI [1])
Steroid therapy | Prednisone U/day allowed | Prednisone Equivalent allowed
Item
ongoing therapy with corticosteroids. prednisone ≤15 mg per day or its equivalent is allowed.
boolean
C0149783 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
C0032952 (UMLS CUI [3,1])
C0205163 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])